Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
21.21B
Market cap21.21B
Price-Earnings ratio
-17.04
Price-Earnings ratio-17.04
Dividend yield
Dividend yield
Average volume
4.29M
Average volume4.29M
High today
$98.51
High today$98.51
Low today
$93.92
Low today$93.92
Open price
$95.88
Open price$95.88
Volume
4.51M
Volume4.51M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$90.39
52 Week low$90.39

Stock Snapshot

As of today, Insmed Incorporated(INSM) shares are valued at $97.85. The company's market cap stands at 21.21B, with a P/E ratio of -17.04.

On 2026-06-13, Insmed Incorporated(INSM) stock moved within a range of $93.92 to $98.51. With shares now at $97.85, the stock is trading +4.2% above its intraday low and -0.7% below the session's peak.

Trading volume for Insmed Incorporated(INSM) stock has reached 4.51M, versus its average volume of 4.29M.

The stock's 52-week range extends from a low of $90.39 to a high of $212.75.

The stock's 52-week range extends from a low of $90.39 to a high of $212.75.

INSM News

TipRanks 2d
Insmed’s New TPIP Liver Study Marks a Small but Important De‑Risking Step

Insmed (INSM) announced an update on their ongoing clinical study. Insmed Inc. has launched a Phase 1 trial called “An Open-label, Phase 1 Trial to Evaluate th...

TipRanks 3d
Insmed Advances Phase 3 Inhaled PAH Therapy, Keeping Growth Hopes Alive

Insmed (INSM) announced an update on their ongoing clinical study. Insmed’s new Phase 3 trial, officially titled “A Phase 3, Randomized, Double-Blind, Placebo-...

TipRanks 5d
Insmed stock price decline a ‘buying opportunity’, says Roth Capital

Roth Capital keeps a Buy rating and a $212 price target on Insmed (INSM). The 10% decline in the stock on Friday is a buying opportunity with a move driven by a...

Analyst ratings

100%

of 22 ratings
Buy
100%
Hold
0%
Sell
0%

More INSM News

Simply Wall St 6d
A Look At Insmed Valuation As Brensocatib Gains Early Traction And New Equity Awards Signal Growth - simplywall.st

...

A Look At Insmed Valuation As Brensocatib Gains Early Traction And New Equity Awards Signal Growth - simplywall.st

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.